Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: Timing and prognosis

Clinical Interventions in Aging

Volumn 9, Issue , 2014, Pages 141-145

  Canan, Handan ^a   Sizmaz, Selçuk ^b   Altan Yaycioǧlu, Rana ^a   Saritürk, Çaǧla ^a   Yilmaz, Gürsel ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Age related macular degeneration (AMD); Optical coherence tomography (OCT); Ranibizumab; Visual acuity

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DISEASE DURATION; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; EARLY INTERVENTION; EXUDATIVE MACULAR DEGENERATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONSET AGE; OPTICAL RESOLUTION; OUTCOME ASSESSMENT; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VERY ELDERLY; VISUAL ACUITY;

AGE-RELATED MACULAR DEGENERATION (AMD); OPTICAL COHERENCE TOMOGRAPHY (OCT); RANIBIZUMAB; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROGNOSIS; RETINA; RETROSPECTIVE STUDIES; TIME FACTORS; VISUAL ACUITY;

EID: 84892398840     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S56863     Document Type: Article

References (19)

1. Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008;2: 377-388.
2. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642.
3. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220-1231.
4. Kvanta A, Algvere PV, Berglin L, Sereqard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37: 1929-1934.
5. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154-162.
6. Rauch R, Weingessel B, Maca SM, Vecsei-Marlovits PV. Time to first treatment: the significance of early treatment of exudative age-related macular degeneration. Retina. 2012;32:1260-1264.
7. Kaiser PK, Brown DM, Zhang K, etal. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850-857.
8. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6 and 9 month results. Eye (Lond). 2008;22:82-86.
9. Rosenfeld PJ, Brown DM, Heier JS, etal. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
10. Brown DM, Kaiser PK, Michels M, etal. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
11. Mitchell P, Korobelnik JF, Lanzetta P, etal. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94:2-13.
12. Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol. 2005;40:313-319.
13. Vander JF, Morgan CM, Schatz H. Growth rate of subretinal neovascularization in age-related macular degeneration. Ophthalmology. 1989;96:1422-1426.
14. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731-1739.
15. Fong AH, Lai TY. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging. 2013;8:467-483.
16. Fung AE, Lalwani GA, Rosenfeld PJ, etal. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
17. Lalwani GA, Rosenfeld PJ, Fung AE, etal. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.
18. Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251:453-458.
19. Muether PS, Hermann MM, Koch K, Fauser S. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol. 2011;249:633-637.